USA flag logo/image

An Official Website of the United States Government

Rapid Point-of-Care Test to Detect Bacteriuria and Confirm Urinary Tract…

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2011 / SBIR
Agency Tracking Number:
R44DK085767
Solicitation Year:
2011
Solicitation Topic Code:
NIDDK
Solicitation Number:
PA10-050
Small Business Information
Silver Lake Research Corporation
911 S PRIMROSE AVE, STE N MONROVIA, CA 91016-8403
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2011
Title: Rapid Point-of-Care Test to Detect Bacteriuria and Confirm Urinary Tract Infection
Agency: HHS
Contract: 2R44DK085767-02
Award Amount: $1,000,000.00
 

Abstract:

DESCRIPTION (provided by applicant): This proposal describes Phase II of the development of a rapid point-of-care test kit for the direct measurement of bacteriuria as a diagnostic for urinary tract infections (UTIs). While bacteriuria at a level of 105 CFU/ml is the gold standard for UTI diagnosis, in practice the required urine culture is unfeasible due to the typical 2-day delay in obtaining results. UTI diagnosis is aided by other in-office urinalysis dipsticks, but studies have shown that there is a high rate of misdiagnosis and consequent overtreatment with antibiotics. The proposed test kit will allow, for the first time, a direct dipstick measurement of bacterial concentration in urine within 10 minutes, in time to aid diagnosis of UTI during the initial office visit. The proposed test kit will be a lateral flow immunoassay, similar to a home pregnancy test. In the test design, multiple anti-bacteria monoclonal antibodies (MAbs) will be used to directly bind to bacterial cells in a urine sample, producing a visual +/- result calibrated to ~105 CFU/ml. These MAbs will be selected from the Company's existing collection of gt80 such antibodies. The test utilizes the Company's proprietary SandwichPLUS format, which allows the simultaneous use of multiple antibodies in a single assay and radically shortens development time. In Phase I, the applicant developed a proof-of- concept prototype which was shown to detect six uropathogenic bacteria strains at the target level of 104 - 105 CFU/ml. In Phase II, thetest kit will be further optimized for sensitivity and specificity using a much broader range of uropathogenic isolates, and test procedure will be further improved and simplified. Clinical validation studies will be carried out to determine the real-world performance of the product. At the successful conclusion of Phase II, the test kit will be ready for manufacturing, FDA review, and marketing. The estimated cost of the test to the end user will be 2.00 - 5.00 per test, far less than the cost of urineculture and in line with the cost of current urine dipsticks. PUBLIC HEALTH RELEVANCE: Urinary tract infections are some of the most common cause of physicians' office visits, accounting for over 8,000,000 visits per year in the US. The gold-standard diagnostic method for UTI, urine culture to detect bacteria, is not currently feasible as a routine procedure due to the 2-day delay in obtaining results. This proposal continues the development a simple, inexpensive, 10-minute dipstick test for bacteria in urine, to give physicians the ability to accurately diagnose UTI during the initial office visit by the patient.

Principal Investigator:

Mark Geisberg
626-359-8441
mgeisberg@silverlakeresearch.com

Business Contact:

Mark Geisberg
626-359-8441
mgeisberg@silverlakeresearch.com
Small Business Information at Submission:

SILVER LAKE RESEARCH CORPORATION
911 S PRIMROSE AVE, STE N MONROVIA, CA 91016-8403

EIN/Tax ID: 195438544
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No